Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs.
Routine application of (18)F-labeled peptides for quantitative in vivo receptor imaging of receptor-expressing tissues and quantification of receptor status using PET is limited by the lack of appropriate radiofluorination methods for routine large-scale synthesis of (18)F-labeled peptides. To satisfy this demand, a new (18)F-labeling methodology based on the chemoselective oxime formation between an unprotected aminooxy-functionalized peptide and an (18)F-labeled aldehyde or ketone was investigated and optimized with respect to peptide conjugation.


METHODS
4-[(18)F]Fluorobenzaldehyde ([(18)F]FB-CHO) was prepared from the 4-formyl-N,N,N-trimethylanilinium precursor via direct no-carrier-added (18)F-fluorination (dimethyl sulfoxide, 60 degrees C, 15 min) and purified using a cation-exchange/reversed-phase cartridge system. Radiochemical yields (RCYs) of N-(4-[(18)F]fluorobenzylidene)oxime ([(18)F]FBOA) formation with various aminooxy-modified peptides such as minigastrin, RGD, and octreotate analogs were investigated as a function of reaction time and temperature, peptide concentration, and pH. Biodistribution studies were performed with an [(18)F]FBOA-RGD dimer ((c(RGDfE)HEG)(2)-K-Dpr-[(18)F]FBOA, 60 and 120 min after injection) and a gylcosylated [(18)F]FB-Tyr(3)-octreotate (Gluc-S-Dpr([(18)F]FBOA)TOCA), 10 and 60 min after injection) using M21 and M21L human melanoma and AR42J rat pancreatic tumor-bearing nude mice, respectively.


RESULTS
[(18)F]FB-CHO was obtained in a nonoptimized RCY of 50% within 30 min. At low peptide concentrations (0.5 mmol/L), optimal [(18)F]FBOA-labeling efficiencies (60%-80%) were obtained within 15 min at 60 degrees C and pH 2-3, independently of the peptide used, affording the [(18)F]FBOA-peptides in overall RCYs of up to 40% (from end of bombardment) after purification. Both (c(RGDfE)HEG)(2)-K-Dpr-[(18)F]FBOA and Gluc-S-Dpr([(18)F]FBOA)TOCA showed pharmacokinetics suitable for early (<or=60 min) high-contrast PET imaging, high tumor uptake (2.48 +/- 0.15 %ID/g [RGD] and 21.8 +/- 1.4 %ID/g [TOCA] at 60 min after injection, where %ID/g = percentage injected dose per gram), and tumor-to-organ ratios that compared well with the corresponding [(18)F]fluoropropionyl analogs [(18)F] Galacto-RGD and Gluc-Lys([(18)F]FP)TOCA, which are prepared via multistep procedures.


CONCLUSIONS
Oxime formation between aminooxy-functionalized peptides and an (18)F-labeled aldehyde or ketone-in this case, [(18)F]FB-CHO-combines fast 1-step, high-yield synthesis of an (18)F-labeled prosthetic group stable against in vivo defluorination with rapid, 1-step chemoselective conjugation to unprotected peptides under mild conditions. Thus, it allows fast and straightforward large-scale production of (18)F-labeled peptides for clinical routine PET application. Furthermore, it opens new perspectives to peptide radiohalogenation in general, permitting labeling of the same precursor both with diagnostic ((18)F, (124)I, (120 g)I, (123)I) and therapeutic ((211)At, (131)I) radiohalogens.
Poethko
Thorsten
T
Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Schottelius
Margret
M
Thumshirn
Georgette
G
Hersel
Ulrich
U
Herz
Michael
M
Henriksen
Gjermund
G
Kessler
Horst
H
Schwaiger
Markus
M
Wester
Hans-Jürgen
HJ
D000818:Animals; D005462:Fluorine Radioisotopes; D006219:Halogens; D006801:Humans; D007553:Isotope Labeling; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging; D010091:Oximes; D010455:Peptides; D019275:Radiopharmaceuticals / Q000138:chemical synthesis*; D051381:Rats; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D006219:Halogens; D010091:Oximes; D010455:Peptides; D019275:Radiopharmaceuticals